The present study was designed to determine whether the increase in rat renal ornithine decarboxylase (L-ornithine carboxy-lyase, EC 4.1.1.17) activity after cycloheximide administration was a primary effect on the kidney or was a secondary effect of adrenal or pituitary hormones released in response to the drug. Renal ornithine decarboxylase activity was reduced approximately 70% 1 hr after intraperitoneal administration of doses of cycloheximide that also inhibited renal protein synthesis by 68-95% within 1 hr. Protein synthesis began to recover by the second hour, accompanied by a rise in decarboxylase activity that reached a peak about six times greater than pretreatment values at 8 hr, then gradually declined to preinjection levels by 16 hr. Peak ornitlhine decarboxylase activity was directly proportional to cycloheximide doses up to 250 Mg; larger doses, which almost abolished protein synthesis for 8 hr, were inhibitory. Plasma corticosterone rose rapidly after cycloheximide, reached a peak at 2 hr, then fell to baseline by 8 hr. Corticosterone response was also dose-dependent up to 250 Mg, but larger doses were inhibitory. Adrenalectomy did not reduce decarboxylase activity response to cycloheximide, nor did cortisol administration enhance it. Hypophysectomy greatly reduced baseline renal decarboxylase activity within 9 hr and all but abolished the increase in enzyme activity normally seen after cycloheximide administration to the intact rat. The hypophysectomized animal exhibited apparent increased sensitivity to cyclohieximide, since a smaller dose of the drug caused a reduction in renal protein synthesis similar to that seen with a larger dose in the intact rat. As protein synthesis was recovering in the hypophysectomized animals, renal decarboxylase activity responded adequately to the injection of a crude pituitary extract. These data suggest that renal ornithine decarboxylase turnover is rapid, that baseline activity is maintained by new protein synthesis, and that the increase in renal enzyme activity after cyclolieximide is in large part dependent upon pituitary hormone action.
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In studies of [4C]Ileucine incorporation into renal protein, a wedge of kidney tissue was obtained in a manner similar to that described above and was placed immediately in 1 ml of ice-cold 154 mM NaCl at pH 7.0. The renal tissue was processed according to the method of Siekevitz (15), except that the final precipitate was dissolved in 2 ml of NCS and counted in 10 ml of Spectrafluor in a Packard 3375 liquid scintillation spectrometer. Counting efficiency for 14C ranged from 87 to 91%.
In some experiments, plasma for corticosterone was obtained by femoral venesection under sodium pentobarbital anesthesia. Trunk blood for corticosterone was collected at the time of sacrifice in some instances. Plasma corticosterone determinations were performed as previously described (16) .
RESULTS
Effect of Cycloheximide on Renal Ornithine Decarboxylase Activity. Intact rats were injected with cycloheximide, trunk blood was collected for plasma corticosterone levels at the time of sacrifice, and the kidneys were removed for assay of ornithine decarboxylase activity. During the first hour following cycloheximide treatment, decarboxylase activity fell to about 30% of control levels and remained there for the next hour. Thereafter, a progressive rise in activity occurred, reaching a peak approximately six times higher than control levels 8 hr after cycloheximide, followed by a return to control levels by 16 hr. Plasma corticosterone levels also rose rapidly, reaching a peak 2 hr after cycloheximide administration and then falling toward control levels by 8 hr (Fig. 1 (10, 17, 18) and since there was a substantial early rise in plasma corticosterone after cycloheximide administration, it seemed possible that the subsequent rise in enzyme activity was due, not to cycloheximide itself, but to corticosterone released in response to the stress caused by administration of the drug. To test this hypothesis, we adrenalectomized rats 16 hr before injecting cycloheximide. Adrenalectomy did not significantly affect either the unstimulated level of renal decarboxylase activity or the magnitude of the increase in activity after cycloheximide (Fig. 4) tomized animals prompted further examination of the possible role of the pituitary in the increase in renal decarboxylase activity seen after cycloheximide treatment of the intact rat. One hour after hypophysectomy, animals were given either 154 mM NaCl or 125 /Ag of cycloheximide. Three hours later, a time at which recovery of protein synthesis was apparent in the hypophysectomized animal and sustained pituitary ACTH release was observed in the intact animal, each rat received an injection of an aqueous extract of ovine pituitary tissue. Renal decarboxylase activity was measured 5 hr after the injection of the pituitary extract. Again, there was a small increase in renal enzyme activity in those animals receiving only the antimetabolite (Fig. 7) . In contrast, the pituitary extract increased renal decarboxylase activity to a much higher level. (3, 20, 21) . By 2 hr, renal protein synthesis had begun a progressive return toward normal. By 4 hr, renal decarboxylase activity was already twice the preinjection level and rose to levels four to six times greater than control at 8 hr. Hepatic ornithine decarboxylase activity has been reported to increase after administration of puromycin, another inhibitor of protein synthesis, to intact rats (12, 13) , but an early fall in decarboxylase activity was not observed in these studies. However, basal levels in the liver are so low that they essentially preclude reliable detection of a fall in enzyme activity. The maximum hepatic ornithine decarboxylase response was observed only 3.5 hr after puromycin administration, whereas it required 8 hr to reach the peak observed in the kidney. There are a number of possible explanations for this apparent discrepancy. The drugs themselves may have different time courses of action and of metabolic clearance. Data derived from experiments involving inhibitors of protein synthesis must be interpreted with caution, since these compounds may affect both synthetic and degradative pathways and may also produce effects unrelated to protein synthesis (21) . It is possible that there are isoenzymes of ornithine decarboxylase in various tissues, variably sensitive to inhibitors of protein synthesis. The finding of a single species of this enzyme in the liver of rats treated with thioacetamide (22) does not preclude the possibility that there are tissue-specific ornithine decarboxylase isoenzymes. Two distinct ornithine decarboxylases, one a biosynthetic enzyme and the other an inducible catabolic enzyme, have been identified in Escherichia coli (23) .
The initial fall in renal decarboxylase activity was similar after all doses of cycloheximide administered. This was not an artifact of the assay system, since still lower levels can readily be measured. This finding suggests that the rate of fall was maximal when protein synthesis was inhibited to 32% or less of baseline, and was dependent upon the metabolic half-life of decarboxylase activity. The lowest level of activity after cycloheximide (12 i 1.5 nmol '4CO2/g) is still significantly higher than the levels observed in the rat 9 hr after hypophysectomy (3.6 + 0.6) (P < 0.05). Thus, it is possible that cycloheximide also inhibits the system that metabolically degrades ornithine decarboxylase, "stabilizing" the activity at a reduced level. The subsequent rise in decarboxylase activity, in contrast, was directly related to doses of cycloheximide up to 250 Mg per animal, as was the corticosterone response. Larger doses appeared to be toxic, completely inhibiting protein synthesis for as long as 8 hr and resulting in lower responses of renal decarboxylase activity and adrenal corticosterone secretion and in high mortality in the animals to which they were given.
The rat responds to cycloheximide as to a stress, releasing pituitary ACTH and stimulating adrenal steroidogenesis un-)F til, with sufficiently large doses of the drug, the steroidogenic stimulus of ACTH can be abolished (24) (25) (26) .
The results of hypophysectomy were striking, however. Not only were basal levels of decarboxylase activity reduced to about 12% of normal within 9 hr, but the rise in activity after cycloheximide was all but abolished. This was not due to a more profound or more prolonged effect of cycloheximide upon protein synthesis in the hypophysectomized rat. The time course of recovery of [14C]leucine incorporation after 125 ug of cycloheximide in the hypophysectomized rat was indistinguishable from that after 250 Mg of the drug in the intact animal, yet only a small rise in decarboxylase activity was observed in the hypophysectomized animals. The increased sensitivity of hypophysectomized animals to the antimetabolite is unexplained. Studies in hypophysectomized animals given 125 Mg of cycloheximide demonstrated that a considerable increase in renal decarboxylase activity was stimulated by administration of a single pulse of pituitary extract. Furthermore, the release of pituitary hormones after administration of cycloheximide to the intact rat appears to be sustained, as evidenced in the case of ACTH by the prolonged hypersecretion of adrenal corticosterone.
These data suggest that the early fall in renal ornithine decarboxylase activity after cycloheximide reflects inhibition of new enzyme synthesis and that the subsequent rise in decarboxylase activity requires the action of pituitary factors released in response to the stress of cycloheximide administration.
